<!DOCTYPE html>
<html lang="en">

<head>
  <meta charset="utf-8">
  <meta content="width=device-width, initial-scale=1.0" name="viewport">

  <title>Details</title>
  <meta content="" name="description">
  <meta content="" name="keywords">

  <!-- Favicons -->
  <link href="assets/img/dna.png" rel="icon">
  <link href="assets/img/dna.png" rel="apple-touch-icon">

  <!-- Google Fonts -->
  <link href="https://fonts.googleapis.com/css?family=Open+Sans:300,300i,400,400i,600,600i,700,700i|Raleway:300,300i,400,400i,500,500i,600,600i,700,700i|Poppins:300,300i,400,400i,500,500i,600,600i,700,700i" rel="stylesheet">

  <!-- Vendor CSS Files -->
  <link href="assets/vendor/aos/aos.css" rel="stylesheet">
  <link href="assets/vendor/bootstrap/css/bootstrap.min.css" rel="stylesheet">
  <link href="assets/vendor/bootstrap-icons/bootstrap-icons.css" rel="stylesheet">
  <link href="assets/vendor/boxicons/css/boxicons.min.css" rel="stylesheet">
  <link href="assets/vendor/glightbox/css/glightbox.min.css" rel="stylesheet">
  <link href="assets/vendor/swiper/swiper-bundle.min.css" rel="stylesheet">

  <!-- Template Main CSS File -->
  <link href="assets/css/style.css" rel="stylesheet">

  <!-- =======================================================
  * Template Name: Kelly
  * Template URL: https://bootstrapmade.com/kelly-free-bootstrap-cv-resume-html-template/
  * Updated: Mar 17 2024 with Bootstrap v5.3.3
  * Author: BootstrapMade.com
  * License: https://bootstrapmade.com/license/
  ======================================================== -->
</head>

<body>

  <main id="main">

   <!-- ======= Portfolio Details Section ======= -->
<section id="portfolio-details" class="portfolio-details">
  <div class="container">
    <div class="row gy-4">

      <!-- Image Section with Reduced Size -->
      <div class="col-lg-8">
        <div class="portfolio-details-slider swiper">
          <div class="swiper-wrapper align-items-center">
            <div class="swiper-slide">
              <img src="assets/img/zol1.jpg" alt="" style="max-width: 80%; height: auto;">
            </div>
            <div class="swiper-slide">
              <img src="assets/img/zol2.jpg" alt="" style="max-width: 80%; height: auto;">
            </div>
          </div>
          <div class="swiper-pagination"></div>
        </div>
      </div>

      <!-- Presentation Information Section -->
      <div class="col-lg-4">
        <div class="portfolio-info">
          <h3>Presentation Information</h3>
          <ul>
            <li><strong>Title</strong>: Presentation on the structure and mechanism of action of the gene therapy drug Zolgensma used in the treatment of SMA patients</li>
            <li><strong>Instructor</strong>: <a href="https://scholar.google.com/citations?user=vnLZGu4AAAAJ&hl=en"target="_blank" rel="noopener noreferrer"> Dr. Inanloo </a></li>
            <li><strong>Presentation Date</strong>: May 2022</li>
            <li><strong>Presentation</strong>: <a href="https://drive.google.com/file/d/1P5z_-rSME7_Gw5pIOlfB5UCD3SbIdHGk/view?usp=sharing"> View the Presentation </a></li>
          </ul>
        </div>
      </div>

      <!-- Presentation Summary Section - Full width below images -->
      <div class="col-12">
        <div class="portfolio-description">
          <h2>Presentation Summary</h2>
          <p>
            Spinal Muscular Atrophy (SMA) is a group of hereditary diseases that progressively destroys the motor neurons and will eventually lead to muscle weakness and atrophy. In children with SMA, the SMN1 gene is missing or not working properly. Zolgensma (Onasemnogene abeparvovec-xioi) is a gene therapy drug that replaces the function of the missing or non-working SMN1 gene with a working SMN gene carried by an Adeno-Associated Virus (AAV) carrier. The genome map of the virus is reviewed in order to identify suitable locations for therapy gene insertion and the reasons why AAVs make good vectors such as low pathogenicity and low immune response are discussed. In addition, gene delivery mechanism along with pharmacokinetics and pharmacodynamics of the drug are reviewed. The ethical and financial issues associated with Zolgensma production and usage are the final topics of the lecture.
          </p>
        </div>
      </div>

    </div>
  </div>
</section><!-- End Portfolio Details Section -->

  </main><!-- End #main -->

  <div id="preloader"></div>
  <a href="#" class="back-to-top d-flex align-items-center justify-content-center"><i class="bi bi-arrow-up-short"></i></a>

  <!-- Vendor JS Files -->
  <script src="assets/vendor/purecounter/purecounter_vanilla.js"></script>
  <script src="assets/vendor/aos/aos.js"></script>
  <script src="assets/vendor/bootstrap/js/bootstrap.bundle.min.js"></script>
  <script src="assets/vendor/glightbox/js/glightbox.min.js"></script>
  <script src="assets/vendor/isotope-layout/isotope.pkgd.min.js"></script>
  <script src="assets/vendor/swiper/swiper-bundle.min.js"></script>
  <script src="assets/vendor/waypoints/noframework.waypoints.js"></script>
  <script src="assets/vendor/php-email-form/validate.js"></script>

  <!-- Template Main JS File -->
  <script src="assets/js/main.js"></script>

</body>

</html>
